

PHARMACY POLICY STATEMENT

BILLING CODE	Must use valid NDC code
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home/Outpatient
STATUS	Prior Authorization Required

Camzyos is a cardiac myosin inhibitor initially approved by the FDA in 2022. It is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Hypertrophic cardiomyopathy is the most common inherited cardiovascular disorder, affecting approximately 1 in 500 individuals worldwide. About two-thirds of patients with HCM are diagnosed with oHCM. Camzyos is the first FDA-approved cardiac myosin inhibitor that targets the underlying pathophysiology of oHCM.

